Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Myeloid Leukemia
Xanthus Presents Data Supporting Distinctive Mechanism of Action for Xanafide(R)
May 4th, 2008
Xanthus Pharmaceuticals, Inc. announced results from three collaborative in vitro studies into the mechanism of action of Xanafide(R) (amonafide malate). Xanafide is a topoisomerase II inhibitor that is currently in a pivotal Phase 3 trial under a special protocol agreement (SPA) with the FDA for the treatment of secondary acute myeloid leukemia (AML). These in vitro studies, presented on April 13 and 14 at the American Association for Cancer Research (AACR) Annual meeting demonstrated how Xanafide acts differently from classical topoisomerase inhibitors such as daunorubicin. Data from these studies showed that Xanafide triggered a similar level of apoptosis but with...
Source: Pharma Investments, Ventures & Law Weekly (2008-05-04)
|
